IPSEF News and Press, Ipsen Sa Ord From 02/11/22

Ipsen S.A. (IPSEY) Q4 2021 Earnings Conference Call February 11, 2022, 8:00 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Group Chief Financial Officer Howard Mayer – Head of Research and Development Conference Call Participants Je...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

Meme-stock favorite AMC (NYSE:AMC) returned to the headlines during Friday's midday trading, posting a double-digit percentage gain on strong early box office totals for the new Spider-Man movie. Elsewhere in the market, drug development news prompted notable gains in Novavax (NASDAQ:NVAX) an...

The following slide deck was published by Ipsen S.A. in conjunction with this event. For further details see: Ipsen S.A. (IPSEY) Investor Presentation - Slideshow

Mirati Therapeutics (MRTX +4.9%) has reached a four-month high amid a series of catalysts, including the appointment of the industry veteran David Meek as the new CEO. Mr. Meek will assume duties as the CEO and will join the company board effective immediately, Mirati (NASDAQ:MRTX) said ...

Ipsen (OTCPK:IPSEY) and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome. Under the agreement, Ipsen will rec...

Ipsen S.A. (IPSEY) Q2 2021 Earnings Conference Call July 29, 2021 08:30 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - EVP and Group CFO Conference Call Participants Elizabeth Walton - Credit Suisse Sachin Jain, Bank - America Delphine Le Louet - Societe Generale Rosie Tur...

The following slide deck was published by Ipsen S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Ipsen S.A. 2021 Q1 - Results - Earnings Call Presentation

Sohel_Parvez_Haque/iStock via Getty Images Exelixis, (EXEL) down 6% premarket and Ipsen (IPSEY) announce that Phase 3 COSMIC-312 trial evaluating cabozantinib (Cabometyx) in combination with Roche's (RHHBY) atezolizumab vs. sorafenib in patients with previously untreated advanced he...

Ipsen (IPSEY) to buyback 500K shares, or about 0.6% of the share capital, over a maximum period of six months.The shares purchased under this agreement will be allocated mainly to cover its free performance share-allocation plans and its new employee share-ownership plan. For further detail...